Clinical Trials Logo

Treatment Related Cancer clinical trials

View clinical trials related to Treatment Related Cancer.

Filter by:
  • None
  • Page 1

NCT ID: NCT05217069 Active, not recruiting - Clinical trials for Treatment Related Cancer

FOLFIRI + Cetuximab + Avelumab RAS Wild-type CRC

Start date: September 27, 2019
Phase: Phase 2
Study type: Interventional

Within the proposed single arm multicenter phase-II trial it is intended to investigate the feasi-bility of adding Avelumab to FOLFIRI plus Cetuximab after 4 cycles (2 months) of treatment with FOLFIRI plus Cetuximab. After 4 more cycles of FOLFIRI plus Cetuximab plus Avelumab the treatment will be de-escalated to Avelumab as a maintenance concept until progression of the disease according to RECIST 1.1 has occurred.

NCT ID: NCT05185388 Active, not recruiting - Diagnoses Disease Clinical Trials

Socioeconomic Inequalities in the Diagnosis and Treatment of Colon and Ovarian Cancer in England Between 2016-2017

Start date: October 25, 2021
Phase:
Study type: Observational

This study is a population-based, patient-level analysis of colon and ovarian cancer diagnoses in England over a 2-year period using a dataset created by linking NCRAS and NHS digital datasets. Our analyses will look into inequalities in the diagnostic and treatment pathway, and inequalities in treatment received, for those diagnosed with colon and ovarian cancer between 2016-2017.

NCT ID: NCT04253249 Withdrawn - Clinical trials for Treatment Related Cancer

Pancreatic Cyst Ablation With a Monopolar Radiofrequency Ablation Probe

Start date: May 1, 2018
Phase:
Study type: Observational [Patient Registry]

Pancreatic cysts (A cyst is a thin walled cavity containing fluid) were rarely reported previously, but have been on a rise due to advanced imaging for evaluating pancreatic lesions or other medical reasons has increased detection of pancreatic cysts. Study shows transformation of pancreatic cysts to be 10.8 for every 100,000 women and 13.8 for every 100,000 men. Pancreatic cysts are divided in two groups; serous and mucinous. Serous cysts are thin walled cysts and are not associated with precancer. On the other hand, mucinous cysts have a tendency to progress to pancreatic cancer. Radio frequency ablation (RFA) is an alternative method used for patients who could not or decided to not undergo surgical removal of the cyst. This study is a standard of care study and no changes in regards to the procedure scheduled with the physician will be changed.

NCT ID: NCT04034173 Not yet recruiting - Clinical trials for Treatment Related Cancer

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Start date: August 1, 2019
Phase: Phase 2
Study type: Interventional

The present hypothesis is that anti-EGFR agents are active in tumors with low-level RAS mutation when the majority of tumor cells is still sensitive. While response rate may be high and may reflect sensitivity to anti-EGFR agents, PFS is anticipated to be shorter than in RAS wild-type patients due to the faster development of resistance when sensitive cells are eradicated and when the RAS-mutant anti-EGFR resistant clones become predominant. The characteristics of low-level RAS mutant tumors would be: - Objective response rate (ORR) high (reflecting the sensitive clone) - Progression-free survival (PFS) short (reflecting the more rapid outgrowth of RAS mutant clones)

NCT ID: NCT03377829 Recruiting - Thyroid Cancer Clinical Trials

A Multicenter Trial of PLA vs. Surgery for Treating PTMC

Start date: December 1, 2017
Phase: N/A
Study type: Interventional

This is a multicenter prospective controlled trial of percutaneous laser ablation(PLA) versus conventional surgery for the treatment of papillary thyroid microcarcinoma (PTMC).

NCT ID: NCT03313193 Completed - Clinical trials for Treatment-Related Cancer

Acupressure for Children in Treatment for a Childhood Cancer

ACT-CC
Start date: September 26, 2017
Phase: N/A
Study type: Interventional

Background: Despite advances in symptom management, children undergoing cancer treatment or receiving a chemotherapy-based Hematopoietic Stem Cell Transplant (HSCT) often suffer from moderate to severe symptoms of nausea/vomiting, pain, and fatigue along with psychological distress. Pharmacologic treatments of symptoms can cause side-effects. Patients, parents, and clinicians have expressed interest in including non-pharmacologic approaches to improve symptom management. Acupuncture/acupressure is a promising adjunctive therapy to usual care. More evidence is needed from well-designed trials with larger samples and rigorous designs in order to make definitive recommendations about the routine inclusion of acupressure among pediatric patients being treated for childhood cancer or receiving a HSCT. Design and Methods 100 dyads (one child with one parent/caregiver) will be randomized 1:1 into 2 study arms (50 children in each arm). Arm A participants will be offered usual care and professional acupressure five times weekly (15-20 minute sessions) and a parent/caregiver will be instructed in acupressure delivery for the child as symptoms arise. Arm B participants will receive usual care alone. (At the study end, Arm B parents will be offered acupressure instructions.) Children will be enrolled for ~30 days which can occur with one month of continuous hospital-based treatment or two months of intermittent hospital-based treatment (inpatient or regular outpatient treatment). Parent and child participants will receive a follow-up interview one month after completion of the intervention (Arm A) or the final symptom assessment (Arm B). Significance This is the first study to evaluate the effectiveness and safety of an acupressure intervention to decrease treatment-related symptoms in 100 patients in treatment for a childhood cancer or receiving a chemo-therapy based HSCT.

NCT ID: NCT03293966 Completed - Clinical trials for Treatment Related Cancer

A Coordination Card of Care Relative to the Medicinal Treatments Got Out of it From Hospitalization

Start date: June 1, 2016
Phase:
Study type: Observational [Patient Registry]

The continuity of the medicinal care between the city and the hospital stays a major organizational stake and of safety of patients' therapeutic care.This takeover is more complex when it concerns pathology needed lots of hospitalization and included the intervention of multiple healthcare practionners. This is clearly the case of cancer coverage. The optimization of the therapeutic suppor in town is based on pharmaceutical advice strengthening but also on the pharmaceutical analysis to check the entire treatments' prescription and eventual medicinal interactions which ensue from it.That's why it's important to have a medicinal conciliation that takes into account all the medecine taken or have to be taken by the patient. A specific support was developped by nurses , doctors and pharmacist ; it's a care coordination card that can be put easely in a pocket by the patient. The aim of the study is that this card can be also used as a communication tools by sharing the prescription done at the release of hospital by using an IT link (flea datamatrix) for the patients Via the use of an IT link (flea datamatrix) for the patients whose pathology is complex in term of extra hospital coverage.

NCT ID: NCT00166686 Withdrawn - Clinical trials for Treatment-Related Cancer

Clonidine for Neurocognitive Sequelae

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

The goals of the study are to determine the efficacy of clonidine in the treatment of children with neurocognitive sequelae following the therapy of long term malignancies. In addition, the study hopes to determine the long-term effect of clonidine on children's academic and psychosocial function.